Novel Theranostic Targets for Prostate Cancer Beyond Prostate-Specific Membrane Antigen
PET Clinics · 2026-07 · 21 (3) · 403-413
DOI: 10.1016/j.cpet.2026.02.003 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift PET Clinics, 2026-07. Verfasst von Pedram Heidari und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Biomarkers, Tumor, Antigens, Surface, Radiopharmaceuticals. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 75 Literaturangaben. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Prostate-specific membrane antigen (PSMA)-targeted theranostics have transformed prostate cancer management, but some tumors exhibit low or heterogeneous PSMA expression, limiting eligibility and efficacy for radiopharmaceutical therapy. This review explores emerging biomarkers that may complement or expand beyond PSMA, including gastrin-releasing peptide receptor, fibroblast activation protein, prostate stem cell antigen, CD46, delta-like ligand 3, glypican-3, B7-H3, 6-transmembrane epithelial antigen of the prostate-1, trophoblast cell surface antigen-2, CEACAM5, and vicrostatin. We review their molecular biology, preclinical validation, clinical translation, and ongoing trials. These biomarkers represent diverse biological compartments, broadening the scope of precision radiotheranostics for prostate cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
- Division of Nuclear Medicine and Molecular Imaging Center, Departments of Radiology, Radiation Oncology and Urology, USC Norris Comprehensive Cancer Center, Keck School of Medicine; Department of Biomedical Engineering,…
- Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. Electronic address: esfahanishadi@mgh.harvard.edu.
Förderung
- NCI NIH HHS
Zitieren
APA
Heidari, P., Jadvar, H., Kako, B., & Esfahani, S. A. (2026). Novel Theranostic Targets for Prostate Cancer Beyond Prostate-Specific Membrane Antigen. PET Clinics, 21(3), 403-413. https://doi.org/10.1016/j.cpet.2026.02.003
Vancouver
Heidari P, Jadvar H, Kako B, Esfahani SA. Novel Theranostic Targets for Prostate Cancer Beyond Prostate-Specific Membrane Antigen. PET Clinics. 2026;21(3):403-413. doi:10.1016/j.cpet.2026.02.003
BibTeX
@article{Heidari2026,
author = {Heidari, Pedram and Jadvar, Hossein and Kako, Bashar and Esfahani, Shadi A},
title = {Novel Theranostic Targets for Prostate Cancer Beyond Prostate-Specific Membrane Antigen},
journal = {PET Clinics},
year = {2026},
volume = {21},
number = {3},
pages = {403--413},
doi = {10.1016/j.cpet.2026.02.003}
}
EUVIMED